Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

North America Advanced Wound Care Market

ID: MRFR/Pharma/19802-HCR
128 Pages
Nidhi Mandole
Last Updated: April 06, 2026

North America Advanced Wound Care Market Research Report Information By Product (Dressings (Foam Dressings, Silicone Dressings, Non-silicone Dressings, Collagen Dressings, Hydrofiber Dressings, Wound Contact Layers, Hydrocolloid Dressings, Film Dressings, Alginate Dressings, Hydrogel Dressings, Superabsorbent Dressings, Other Advanced Dressings), Devices & Accessories (NPWT Devices & Accessories, Debridement Devices & Accessories, Wound Assessment & Monitoring Devices, Other Devices & Accessories), Grafts & Matrices, Topical Agents), By Wound Type (Surgical & Traumatic Wounds, Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers, and Burns & Other Wounds), By End User (Hospitals, ASCs, and Wound Care Centers, Home Care Settings, and Other End Users) –North America Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

North America Advanced Wound Care Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Product Type (USD Billion)
  49.     4.1.1 Negative Pressure Wound Therapy
  50.     4.1.2 Advanced Dressings
  51.     4.1.3 Tissue Engineered Skin Substitutes
  52.     4.1.4 Wound Cleansers and Irrigants
  53.     4.1.5 Wound Closure Devices
  54.   4.2 Pharmaceutical, BY Wound Type (USD Billion)
  55.     4.2.1 Diabetic Wounds
  56.     4.2.2 Pressure Ulcers
  57.     4.2.3 Surgical Wounds
  58.     4.2.4 Chronic Wounds
  59.     4.2.5 Burn Wounds
  60.   4.3 Pharmaceutical, BY End User (USD Billion)
  61.     4.3.1 Hospitals
  62.     4.3.2 Clinics
  63.     4.3.3 Ambulatory Surgical Centers
  64.     4.3.4 Nursing Homes
  65.     4.3.5 Home Care Settings
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Pharmaceutical
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Smith & Nephew (GB)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Mölnlycke Health Care (SE)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 3M (US)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Acelity (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 ConvaTec (GB)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Medtronic (IE)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Hollister (US)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 B. Braun (DE)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.     5.2.9 Coloplast (DK)
  131.       5.2.9.1 Financial Overview
  132.       5.2.9.2 Products Offered
  133.       5.2.9.3 Key Developments
  134.       5.2.9.4 SWOT Analysis
  135.       5.2.9.5 Key Strategies
  136.   5.3 Appendix
  137.     5.3.1 References
  138.     5.3.2 Related Reports
  139. 6 LIST OF FIGURES
  140.   6.1 MARKET SYNOPSIS
  141.   6.2 NORTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
  142.   6.3 NORTH AMERICA MARKET ANALYSIS BY WOUND TYPE
  143.   6.4 NORTH AMERICA MARKET ANALYSIS BY END USER
  144.   6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL
  145.   6.6 RESEARCH PROCESS OF MRFR
  146.   6.7 DRO ANALYSIS OF PHARMACEUTICAL
  147.   6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  148.   6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  149.   6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  150.   6.11 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
  151.   6.12 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
  152.   6.13 PHARMACEUTICAL, BY WOUND TYPE, 2024 (% SHARE)
  153.   6.14 PHARMACEUTICAL, BY WOUND TYPE, 2024 TO 2035 (USD Billion)
  154.   6.15 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
  155.   6.16 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Billion)
  156.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  157. 7 LIST OF TABLES
  158.   7.1 LIST OF ASSUMPTIONS
  159.     7.1.1
  160.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  161.     7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  162.     7.2.2 BY WOUND TYPE, 2025-2035 (USD Billion)
  163.     7.2.3 BY END USER, 2025-2035 (USD Billion)
  164.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  165.     7.3.1
  166.   7.4 ACQUISITION/PARTNERSHIP
  167.     7.4.1

North America Pharmaceutical Market Segmentation

Pharmaceutical By Product Type (USD Billion, 2025-2035)

  • Negative Pressure Wound Therapy
  • Advanced Dressings
  • Tissue Engineered Skin Substitutes
  • Wound Cleansers and Irrigants
  • Wound Closure Devices

Pharmaceutical By Wound Type (USD Billion, 2025-2035)

  • Diabetic Wounds
  • Pressure Ulcers
  • Surgical Wounds
  • Chronic Wounds
  • Burn Wounds

Pharmaceutical By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Nursing Homes
  • Home Care Settings

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions